[96a5a0]: / output / allTrials / identified / NCT06561620_identified.json

Download this file

853 lines (853 with data), 39.8 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
{
"info": {
"nct_id": "NCT06561620",
"official_title": "A Prospective Study of Befotertinib Adjuvant Therapy in Patients With Postoperative MRD-positive Non-small Cell Lung Cancer in Stage IA2-IB With High Risk Factors",
"inclusion_criteria": "1. Age: 18-75 years old.\n2. Gender: both men and women are acceptable, as balanced as possible.\n3. Patients with lung adenocarcinoma who underwent R0 resection and were clinically confirmed as IA2-IB by histopathology and whose tumor size was (1-4cm), the surgical tissue samples tested positive for EGFR-sensitive mutations and positive for MRD after surgery.\n4. Accompanied by arbitrary ≥ 2 high-risk factors; High risk factors such as pleural invasion, airway diffusion, vascular infiltration, low differentiation, pathological micropapillary composition ≥ 15%, complex glandular composition ≥ 20%, etc.\n\n4. Achieve R0 resection: For CTR < 50% ground glass nodules, wedge resection is acceptable and the margin is negative, and 3 groups of lymph node biopsies are negative; for CTR ≥ 50% or pure solid nodules, at least segmental resection is undergone, and lymph node dissection is systematically performed; if there is no clear evidence of metastasis, if it cannot be judged, it can be determined by an independent review committee for pathological consultation.\n\n5. The ECOG behavioral status score is 0 to 1, and the expected survival time is > 1 year.\n\n6. Voluntary MRD screening and voluntary befortinib adjuvant therapy; 7. Have a certain organ system function, defined as follows, based on the researcher's experience A. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L B. Platelets ≥ 100 x 109/L; C. Hemoglobin ≥ 9 g/dL (≥ 90 g/L) Note that in order to achieve the required hemoglobin level, blood transfusion is allowed; D. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); E. If there is no liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; if liver metastasis, ≤ 5 × ULN; F. Creatinine ≤ 1.5 x ULN. Patients are still eligible for inclusion if the creatinine clearance value calculated by the Cockcroft-Gault method is ≥ 50 mL/min (0.83 mL/s).\n\n8. Female subjects of childbearing age must have a serum pregnancy test within 3 days before the start of the study drug, and the result is negative, and they are willing to use a medically approved high-efficacy contraceptive method (such as intrauterine devices, contraceptives or condoms) during the study period and within 3 months after the last administration of the study drug; for significant other male subjects who are women of childbearing age, they should be surgically sterilized, or agree to use effective methods of contraception during the study period and within 3 months after the last study dose.\n\n9. Voluntary and capable of following the test and follow-up procedures. 10. Sign the informed consent form.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "1. There is any other treatment before the operation, and no informed consent is signed;\n2. The patient has been diagnosed with cancer within 2 years;\n3. Have a history of interstitial lung disease, drug-induced interstitial disease or any active interstitial lung disease with clinical evidence; CT scan at baseline revealed idiopathic pulmonary fibrosis.\n4. Patients who are known to be allergic to any component of befortinib or similar drugs;\n5. Pregnant or lactating women;\n6. Situations considered unsuitable for inclusion by other researchers.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. Age: 18-75 years old.",
"criterions": [
{
"exact_snippets": "Age: 18-75 years old.",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 75,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "2. Gender: both men and women are acceptable, as balanced as possible.",
"criterions": [
{
"exact_snippets": "Gender: both men and women are acceptable",
"criterion": "gender",
"requirements": [
{
"requirement_type": "acceptable genders",
"expected_value": [
"men",
"women"
]
}
]
},
{
"exact_snippets": "as balanced as possible",
"criterion": "gender balance",
"requirements": [
{
"requirement_type": "balance",
"expected_value": "as balanced as possible"
}
]
}
]
},
{
"line": "3. Patients with lung adenocarcinoma who underwent R0 resection and were clinically confirmed as IA2-IB by histopathology and whose tumor size was (1-4cm), the surgical tissue samples tested positive for EGFR-sensitive mutations and positive for MRD after surgery.",
"criterions": [
{
"exact_snippets": "Patients with lung adenocarcinoma",
"criterion": "lung adenocarcinoma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "underwent R0 resection",
"criterion": "R0 resection",
"requirements": [
{
"requirement_type": "completion",
"expected_value": true
}
]
},
{
"exact_snippets": "clinically confirmed as IA2-IB by histopathology",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"IA2",
"IB"
]
}
]
},
{
"exact_snippets": "tumor size was (1-4cm)",
"criterion": "tumor size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1,
"unit": "cm"
},
{
"operator": "<=",
"value": 4,
"unit": "cm"
}
]
}
}
]
},
{
"exact_snippets": "surgical tissue samples tested positive for EGFR-sensitive mutations",
"criterion": "EGFR-sensitive mutations",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "positive for MRD after surgery",
"criterion": "MRD (Minimal Residual Disease)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. Accompanied by arbitrary ≥ 2 high-risk factors; High risk factors such as pleural invasion, airway diffusion, vascular infiltration, low differentiation, pathological micropapillary composition ≥ 15%, complex glandular composition ≥ 20%, etc.",
"criterions": [
{
"exact_snippets": "pleural invasion",
"criterion": "pleural invasion",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "airway diffusion",
"criterion": "airway diffusion",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "vascular infiltration",
"criterion": "vascular infiltration",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "low differentiation",
"criterion": "low differentiation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "pathological micropapillary composition ≥ 15%",
"criterion": "pathological micropapillary composition",
"requirements": [
{
"requirement_type": "composition",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "%"
}
}
]
},
{
"exact_snippets": "complex glandular composition ≥ 20%",
"criterion": "complex glandular composition",
"requirements": [
{
"requirement_type": "composition",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "%"
}
}
]
}
]
},
{
"line": "4. Achieve R0 resection: For CTR < 50% ground glass nodules, wedge resection is acceptable and the margin is negative, and 3 groups of lymph node biopsies are negative; for CTR ≥ 50% or pure solid nodules, at least segmental resection is undergone, and lymph node dissection is systematically performed; if there is no clear evidence of metastasis, if it cannot be judged, it can be determined by an independent review committee for pathological consultation.",
"criterions": [
{
"exact_snippets": "CTR < 50% ground glass nodules",
"criterion": "CTR ground glass nodules",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "%"
}
},
{
"requirement_type": "type",
"expected_value": "ground glass"
}
]
},
{
"exact_snippets": "wedge resection is acceptable",
"criterion": "wedge resection",
"requirements": [
{
"requirement_type": "acceptability",
"expected_value": true
}
]
},
{
"exact_snippets": "the margin is negative",
"criterion": "resection margin",
"requirements": [
{
"requirement_type": "status",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "3 groups of lymph node biopsies are negative",
"criterion": "lymph node biopsies",
"requirements": [
{
"requirement_type": "number of groups",
"expected_value": {
"operator": "=",
"value": 3,
"unit": "groups"
}
},
{
"requirement_type": "status",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "CTR ≥ 50% or pure solid nodules",
"criterion": "CTR solid nodules",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
},
{
"requirement_type": "type",
"expected_value": "solid"
}
]
},
{
"exact_snippets": "at least segmental resection is undergone",
"criterion": "segmental resection",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
},
{
"exact_snippets": "lymph node dissection is systematically performed",
"criterion": "lymph node dissection",
"requirements": [
{
"requirement_type": "systematic performance",
"expected_value": true
}
]
},
{
"exact_snippets": "no clear evidence of metastasis",
"criterion": "evidence of metastasis",
"requirements": [
{
"requirement_type": "clarity",
"expected_value": "none"
}
]
},
{
"exact_snippets": "determined by an independent review committee for pathological consultation",
"criterion": "independent review committee determination",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
}
]
},
{
"line": "5. The ECOG behavioral status score is 0 to 1, and the expected survival time is > 1 year.",
"criterions": [
{
"exact_snippets": "ECOG behavioral status score is 0 to 1",
"criterion": "ECOG behavioral status score",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "expected survival time is > 1 year",
"criterion": "expected survival time",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "year"
}
}
]
}
]
},
{
"line": "6. Voluntary MRD screening and voluntary befortinib adjuvant therapy; 7. Have a certain organ system function, defined as follows, based on the researcher's experience A. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L B. Platelets ≥ 100 x 109/L; C. Hemoglobin ≥ 9 g/dL (≥ 90 g/L) Note that in order to achieve the required hemoglobin level, blood transfusion is allowed; D. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); E. If there is no liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; if liver metastasis, ≤ 5 × ULN; F. Creatinine ≤ 1.5 x ULN. Patients are still eligible for inclusion if the creatinine clearance value calculated by the Cockcroft-Gault method is ≥ 50 mL/min (0.83 mL/s).",
"criterions": [
{
"exact_snippets": "Voluntary MRD screening",
"criterion": "MRD screening",
"requirements": [
{
"requirement_type": "voluntary",
"expected_value": true
}
]
},
{
"exact_snippets": "voluntary befortinib adjuvant therapy",
"criterion": "befortinib adjuvant therapy",
"requirements": [
{
"requirement_type": "voluntary",
"expected_value": true
}
]
},
{
"exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 109/L",
"criterion": "absolute neutrophil count (ANC)",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1.5,
"unit": "x 10^9/L"
}
}
]
},
{
"exact_snippets": "Platelets ≥ 100 x 109/L",
"criterion": "platelets",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100,
"unit": "x 10^9/L"
}
}
]
},
{
"exact_snippets": "Hemoglobin ≥ 9 g/dL (≥ 90 g/L)",
"criterion": "hemoglobin",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 9,
"unit": "g/dL"
}
}
]
},
{
"exact_snippets": "Total bilirubin ≤ 1.5 times the upper limit of normal (ULN)",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "x ULN"
}
}
]
},
{
"exact_snippets": "alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; if liver metastasis, ≤ 5 × ULN",
"criterion": "alanine aminotransferase (ALT) and aspartate aminotransferase (AST)",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2.5,
"unit": "x ULN"
},
{
"operator": "<=",
"value": 5,
"unit": "x ULN"
}
]
}
}
]
},
{
"exact_snippets": "Creatinine ≤ 1.5 x ULN",
"criterion": "creatinine",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "x ULN"
}
}
]
},
{
"exact_snippets": "creatinine clearance value calculated by the Cockcroft-Gault method is ≥ 50 mL/min (0.83 mL/s)",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "mL/min"
}
}
]
}
]
},
{
"line": "8. Female subjects of childbearing age must have a serum pregnancy test within 3 days before the start of the study drug, and the result is negative, and they are willing to use a medically approved high-efficacy contraceptive method (such as intrauterine devices, contraceptives or condoms) during the study period and within 3 months after the last administration of the study drug; for significant other male subjects who are women of childbearing age, they should be surgically sterilized, or agree to use effective methods of contraception during the study period and within 3 months after the last study dose.",
"criterions": [
{
"exact_snippets": "Female subjects of childbearing age",
"criterion": "gender and reproductive status",
"requirements": [
{
"requirement_type": "gender",
"expected_value": "female"
},
{
"requirement_type": "reproductive status",
"expected_value": "childbearing age"
}
]
},
{
"exact_snippets": "serum pregnancy test within 3 days before the start of the study drug, and the result is negative",
"criterion": "serum pregnancy test",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 3 days before the start of the study drug"
},
{
"requirement_type": "result",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "willing to use a medically approved high-efficacy contraceptive method (such as intrauterine devices, contraceptives or condoms) during the study period and within 3 months after the last administration of the study drug",
"criterion": "contraceptive use",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "method",
"expected_value": [
"intrauterine devices",
"contraceptives",
"condoms"
]
},
{
"requirement_type": "duration",
"expected_value": "during the study period and within 3 months after the last administration of the study drug"
}
]
},
{
"exact_snippets": "significant other male subjects who are women of childbearing age",
"criterion": "significant other gender and reproductive status",
"requirements": [
{
"requirement_type": "gender",
"expected_value": "male"
},
{
"requirement_type": "partner reproductive status",
"expected_value": "women of childbearing age"
}
]
},
{
"exact_snippets": "surgically sterilized, or agree to use effective methods of contraception during the study period and within 3 months after the last study dose",
"criterion": "contraceptive or sterilization status",
"requirements": [
{
"requirement_type": "sterilization",
"expected_value": "surgically sterilized"
},
{
"requirement_type": "contraceptive use",
"expected_value": "agree to use effective methods of contraception"
},
{
"requirement_type": "duration",
"expected_value": "during the study period and within 3 months after the last study dose"
}
]
}
]
},
{
"line": "9. Voluntary and capable of following the test and follow-up procedures. 10. Sign the informed consent form.",
"criterions": [
{
"exact_snippets": "Voluntary",
"criterion": "voluntary participation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "capable of following the test and follow-up procedures",
"criterion": "capability to follow procedures",
"requirements": [
{
"requirement_type": "capability",
"expected_value": true
}
]
},
{
"exact_snippets": "Sign the informed consent form",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. There is any other treatment before the operation, and no informed consent is signed;",
"criterions": [
{
"exact_snippets": "any other treatment before the operation",
"criterion": "prior treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "no informed consent is signed",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": false
}
]
}
]
},
{
"line": "2. The patient has been diagnosed with cancer within 2 years;",
"criterions": [
{
"exact_snippets": "The patient has been diagnosed with cancer within 2 years",
"criterion": "cancer diagnosis",
"requirements": [
{
"requirement_type": "time since diagnosis",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "3. Have a history of interstitial lung disease, drug-induced interstitial disease or any active interstitial lung disease with clinical evidence; CT scan at baseline revealed idiopathic pulmonary fibrosis.",
"criterions": [
{
"exact_snippets": "history of interstitial lung disease",
"criterion": "interstitial lung disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "drug-induced interstitial disease",
"criterion": "drug-induced interstitial disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "any active interstitial lung disease with clinical evidence",
"criterion": "active interstitial lung disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "CT scan at baseline revealed idiopathic pulmonary fibrosis",
"criterion": "idiopathic pulmonary fibrosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. Patients who are known to be allergic to any component of befortinib or similar drugs;",
"criterions": [
{
"exact_snippets": "Patients who are known to be allergic to any component of befortinib",
"criterion": "allergy to befortinib components",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "allergic to ... similar drugs",
"criterion": "allergy to similar drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "5. Pregnant or lactating women;",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lactating women",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "6. Situations considered unsuitable for inclusion by other researchers.",
"criterions": [
{
"exact_snippets": "Situations considered unsuitable for inclusion by other researchers.",
"criterion": "suitability for inclusion",
"requirements": [
{
"requirement_type": "determination",
"expected_value": "unsuitable by other researchers"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}